Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2015 May;30(5):533-41.
doi: 10.3346/jkms.2015.30.5.533. Epub 2015 Apr 15.

Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma

Hyung Kyu Park  1 , HyunKyung Kim  1 , Hyeong-Gon Kim  2 , Young Mee Cho  3 , Woon Yong Jung  4 , Hye Seung Han  1 , Tae Sook Hwang  1 , Ghee Young Kwon  5 , So Dug Lim  1
Affiliations

"VSports在线直播" Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma

Hyung Kyu Park et al. J Korean Med Sci. 2015 May.

V体育2025版 - Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-activated transcription factor has been investigated as the target for cancer treatment as well as metabolic disorders. Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects. The aim of this study was to validate PPAR-γ expression in malignant and benign prostate tissues by immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). A total of 730 prostatic adenocarcinomas (PCAs) including 63 whole sections from radical prostatectomy specimens and tissue microarrays containing 667 PCAs were subject to immunostaining for two PPAR-γ antibodies. Twenty-five benign prostate tissues and PCAs were selected for investigating mRNA expression by quantitative real-time PCR. 10. 7% of PCAs (78/730) showed cytoplasmic immunoreactivity of PPAR-γ and no nuclear immunoreactivity was noted in PCAs. Most benign prostatic glands showed negative immunoreactivity of PPAR-γ except for variable weak cytoplasmic staining in some glands. Nuclear immunoreactivity of PPAR-γ was noted some central zone and verumontanum mucosal epithelium VSports手机版. The constitutive PPAR-γ mRNA showed significantly lower level in PCAs compared to that in the benign tissues. There was no difference of PPAR-γ mRNA expression between low (≤7) and high (>7) Gleason score groups. There was no association of PPAR-γ mRNA level or cytoplasmic immunostaining with Gleason grade or pathologic stage. Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-γ. Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic implication in prostate cancer. .

Keywords: Immunohistochemistry; PPAR gamma; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction. V体育安卓版.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE: The authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. PPAR-γ protein expression in prostate adenocarcinomas (PCAs) of tissue microarrays (TMA) by immunohistochemistry. (A) No cytoplasmic or nuclear expression (×400). (B) Diffuse cytoplasmic expression (×400).
Fig. 2
Fig. 2. PPAR-γ protein expression in PCAs of whole sections by immunohistochemistry. (A-C) Diffuse cytoplasmic expression in carcinomas (arrow head) compared to the benign prostatic epithelial cells (*) (×400). (D) Tumor heterogeneity, negative (arrow) and positive (arrow head) (×200).
Fig. 3
Fig. 3. PPAR-γ protein expression in benign prostate tissues by immunohistochemistry. (A) Variable weak cytoplasmic staining mainly in basal cells in benign glands. (B) Nuclear immunostaining in verumontanum mucosal epithelium. (C-D) Nuclear or cytoplasmic staining in the epithelium of benign prostatic hyperplasia (×400).
Fig. 4
Fig. 4. PPAR-γ protein expression in positive control tissues by immunohistochemistry. Nuclear immunoreactivity in thyroid follicular carcinoma (A), urothelial carcinoma (B), and adipocytes in periprostatic tissue (C) (Original magnification: (A, C) ×400; (B) ×200).
Fig. 5
Fig. 5. Expression of PPAR-γ mRNA. (A) Comparison of the mean fold change between controls, low GS (Gleason score ≤ 7) and high GS (Gleason score > 7) groups of PCAs. (B) Fold change in each sample of low GS (Low1-10) and high GS (High1-10) groups.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4:486–501. - PMC - PubMed
    1. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11. - PMC - PubMed
    1. Helpap B, Ringli D, Shaikhibrahim Z, Wernert N, Kristiansen G. The heterogeneous Gleason 7 carcinoma of the prostate: analyses of low and high grade (risk) carcinomas with criteria of the International Society of Urological Pathology (ISUP) Pathol Res Pract. 2013;209:190–194. - PubMed
    1. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131. - PubMed (V体育2025版)

Publication types

MeSH terms